Stock fact sheet · data as of

Bruker Corporation (BRKR): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · Speculative / Distressed

Close56.54
GLS fair value18.803 of 9 models
Margin of safety-201%price above fair value
Wheel Score45Weakcapped at 45
Health5/9Piotroski F-score
Moat3.7/10GLS 10-year score
Market cap$8.6B2.1M shares a day
Implied vol.67%near-the-money, 20-60 d
P/E-EPS -0.47
Dividend yield0.35%payout -77%
Beta1.22moves more than the market
Next earnings2 Nov 2026in 17 days (before the open)

Is BRKR undervalued?

BRKR closed at 56.54 on 16 Oct 2026, more than 30% above the GLS average fair value of 18.80. Only 0 of the 3 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.

The average is built from just 3 models (DCF, 10 Cap, DDM) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.

The nightly engine files BRKR under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for BRKR

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF33.47-41%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap19.99-65%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM2.94-95%Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-9.97-118%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target67.00+19%Analysts' average 12-month price target. Not in the average

Quality and financial health

Bruker Corporation scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 3.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -0.2%, ROE -0.4%, ROA -0.1% - with debt at 0.83 times equity and a free-cash-flow yield of 1.1%.

The dividend yield is 0.35% with a payout ratio of -77% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Product 79%, Product and Service, Other 21% (quarter Q2 FY2026).

Institutional ownership scores 10/10, insider activity 3/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score5 / 9ROIC-0.2%
GLS Moat3.7 / 10ROE-0.4%
Debt / equity0.83ROA-0.1%
Free-cash-flow yield1.1%Payout ratio-77%
Institutions10 / 10Insiders · Congress3 · 5 / 10

Wheel Score 45: Weak

With a Wheel Score of 45 Bruker Corporation sits in the Weak band, capped at 45 because the engine files it as Speculative / Distressed. The parts - Value 0/25, Health 11/20, Moat 6/15, Premium 18/20, Stability 20/20 - show where: Value (0/25) scores lowest.

Implied volatility is 67% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (18 of 20) because volatility this high usually comes with a reason. Chain open interest is 7,296 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 2.1M shares a day on a market cap of $8.6B, with a beta of 1.22 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 20 of 20.

PartPointsFrom
Value0 / 25-201% margin of safety
Health11 / 20Piotroski 5/9
Moat6 / 15moat 3.7/10
Premium18 / 20implied volatility 67%
Stability20 / 202.1M shares/day, $8.6B cap, beta 1.22

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 2 Nov 2026 (before the open), 17 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to Bruker Corporation by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
BRKRP
Bruker Corporation
417.6227.00-1447%28No options$8.6B
PODD
Insulet Corp.
133.93153.23+13%88Prime$9.3B
GKOS
Glaukos Corporation
165.60--45Weak$9.8B
BIO
Bio-Rad Laboratories, Inc.
364.82246.29-48%58Fair$9.8B
GMED
Globus Medical, Inc.
78.84112.94+30%92Prime$10.6B
ALGN
Align Technology, Inc.
149.34125.50-19%66Good$10.6B
SNN
Smith & Nephew plc
27.8837.94+27%90Prime$11.7B
PEN
Penumbra, Inc.
320.12139.38-130%54Fair$12.6B
HAE
Haemonetics Corporation
121.2965.74-84%60Fair$5.5B
LIVN
LivaNova PLC
78.5099.67+21%82Prime$4.3B
ITGR
Integer Holdings Corporation
126.7278.09-62%47Weak$4.3B
ZBH
Zimmer Biomet Holdings, Inc.
91.77134.51+32%87Prime$17.5B

⚖ Compare BRKR with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about BRKR

Is BRKR undervalued right now?

No: at 56.54 the stock trades 201% above the GLS average fair value of 18.80 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of BRKR and what does it mean?

BRKR scores 45 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for BRKR?

18.80 per share as of 16 Oct 2026 - the simple average of the 3 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Bruker Corporation report earnings next?

The next earnings report is due on 2 Nov 2026 (before the open), 17 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does BRKR have listed options, and how liquid are they?

Yes. The nightly snapshot found 260 listed contracts with 7,296 open interest across all expiries and implied volatility of 67% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.